Thanks To Evergreening And Legal Threats, AbbVie Has Earned $114 Billion Since 2016 From A Drug Whose Key Patent Expired Back Then
Techdirt has been writing about evergreening — making small changes to a drug, often about to come off patent, in order to gain a new patent that extends its manufacturer’s control over it — for ten years now. The evergreening approach betrays the implicit bargain that lies at the heart of patents — that a...arthritis·biosimilars